Actinium Pharmaceuticals (STU:7AY1) Debt-to-Equity : 0.05 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals Debt-to-Equity?

Actinium Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.51 Mil. Actinium Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.32 Mil. Actinium Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €40.35 Mil. Actinium Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Actinium Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

STU:7AY1' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.15 Med: 0.02 Max: 0.43
Current: 0.05

During the past 13 years, the highest Debt-to-Equity Ratio of Actinium Pharmaceuticals was 0.43. The lowest was -0.15. And the median was 0.02.

STU:7AY1's Debt-to-Equity is ranked better than
72.97% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs STU:7AY1: 0.05

Actinium Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Actinium Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Debt-to-Equity Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.25

0.01

0.04

0.06

Actinium Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.04	0.05	0.06	0.05

Competitive Comparison of Actinium Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Actinium Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Debt-to-Equity falls into.

Actinium Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Actinium Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.496	+	1.442)	/	33.36
	=	0.06

Actinium Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.507	+	1.317)	/	40.348
	=	0.05

Actinium Pharmaceuticals (STU:7AY1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Actinium Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals (STU:7AY1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ATNM:USA 7AY1:Germany

Address

275 Madison Avenue, 7th Floor, New York, NY, USA, 10016

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (STU:7AY1) Headlines

No Headlines